Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
54
Recruiting, any sponsor type, condition "seizures"
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed475
54 trials
Showing 1 to 25, recently updated first.
Aeovian Pharmaceuticals, Inc.Industry
NCT07680322 · 42 participants (planned) · Start Oct 5, 2026 · Primary completion Sep 1, 2027
Drug: AV078; Placebo · For: Tuberous Sclerosis Complex; Epilepsy
Sites: London, Canada
- A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged SeizuresPivotal-lookingRecruiting
NCT05077904 · 350 participants (planned) · Start Dec 7, 2021 · Primary completion Mar 29, 2027
Drug: Staccato alprazolam · For: Stereotypical Prolonged Seizures
Sites: Phoenix, Arizona; Scottsdale, Arizona; Little Rock, Arkansas · 183 sites in all
- Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-2Pivotal-lookingRecruiting
Rapport Therapeutics Inc.Industry
NCT07594119 · 312 participants (planned) · Start Sep 1, 2026 · Primary completion Jul 2029
Drug: RAP-219; RAP-219 · For: Focal Seizure; Epilepsy; Focal Epilepsy
Sites: Huntsville, Alabama; Bentonville, Arkansas; Colorado Springs, Colorado · 17 sites in all
- A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset SeizuresRecruiting
Rapport Therapeutics Inc.Industry
NCT07219407 · 30 participants (planned) · Start Dec 15, 2025 · Primary completion Feb 3, 2028
Drug: RAP-219 · For: Focal Epilepsy; Epilepsy; Refractory Focal Epilepsy and 3 more
Sites: Boise, Idaho; Rochester, Minnesota; New York, New York · 7 sites in all
- Methylphenidate for the Treatment of Epilepsy-related Cognitive DeficitsPivotal-lookingRecruiting
VA Office of Research and DevelopmentFederal agency
NCT04419272 · 226 participants (planned) · Start Aug 14, 2023 · Primary completion May 31, 2028
Drug: Methylphenidate; Methylphenidate · For: Epilepsy
Sites: Miami, Florida; Boston, Massachusetts; New York, New York · 4 sites in all
- Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1Pivotal-lookingRecruiting
Rapport Therapeutics Inc.Industry
NCT07563881 · 333 participants (planned) · Start Jun 5, 2026 · Primary completion Jul 2029
Drug: RAP-219; RAP-219 · For: Focal Seizure; Epilepsy; Focal Epilepsy
Sites: Birmingham, Alabama; Palmdale, California; San Francisco, California · 24 sites in all
- Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)Pivotal-lookingRecruiting
University of VirginiaAcademic, hospital or other
NCT06907173 · 770 participants (planned) · Start Mar 6, 2026 · Primary completion Jun 2029
Drug: Levetiracetam (LEV) (60 mg/Kg) + 1 mg/kg Ketamine (KET); Levetiracetam (LEV) (60 mg/Kg) + 3 mg/kg Ketamine (KET) and 1 more · For: Status Epilepticus
Sites: Birmingham, Alabama; Tucson, Arizona; La Jolla, California · 63 sites in all
- Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and AdultsPivotal-lookingRecruiting
SK Life Science, Inc.Industry
NCT05219617 · 252 participants (planned) · Start Apr 28, 2022 · Primary completion Feb 2027
Drug: Carisbamate · For: Seizures; Lennox Gastaut Syndrome
Sites: Palo Alto, California; Jacksonville, Florida; Orlando, Florida · 71 sites in all
- A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)Pivotal-lookingRecruiting
Xenon Pharmaceuticals Inc.Industry
NCT05716100 · 360 participants (planned) · Start May 9, 2023 · Primary completion Jan 2028
Drug: XEN1101; Placebo · For: Focal Onset Seizures
Sites: Little Rock, Arkansas; Downey, California; Los Angeles, California · 103 sites in all
- A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic SeizuresPivotal-lookingRecruiting
Xenon Pharmaceuticals Inc.Industry
NCT05667142 · 160 participants (planned) · Start Feb 14, 2023 · Primary completion Apr 2027
Drug: XEN1101; Placebo · For: Primary Generalized Tonic-Clonic Seizures
Sites: Mobile, Alabama; Phoenix, Arizona; Tucson, Arizona · 141 sites in all
- Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))Pivotal-lookingRecruiting
Neurona TherapeuticsIndustry
NCT05135091 · 88 participants (planned) · Start Jun 16, 2022 · Primary completion Feb 2029
Drug: NRTX-1001; NRTX-1001 · For: Mesial Temporal Lobe Epilepsy
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 36 sites in all
- A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet SyndromePivotal-lookingRecruiting
EpygenixIndustry
NCT04462770 · 150 participants (planned) · Start Sep 15, 2020 · Primary completion Apr 2027
Drug: Clemizole HCl; Placebo · For: Dravet Syndrome
Sites: Birmingham, Alabama; Little Rock, Arkansas; Los Angeles, California · 86 sites in all
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
NCT07233239 · 100 participants (planned) · Start Nov 26, 2025 · Primary completion Nov 29, 2027
Drug: CBD-OS · For: Focal Seizures
Sites: Phoenix, Arizona; La Jolla, California; New Haven, Connecticut · 24 sites in all
- Early Post-Traumatic Seizures Prevention Trial (E-PTS Trial)Pivotal-lookingRecruiting
All India Institute of Medical Sciences, JodhpurGovernment (non-federal)
NCT07072624 · 1,260 participants (planned) · Start Jul 23, 2025 · Primary completion Mar 15, 2027
Drug: Phenytoin; Levetiracetam and 1 more · For: Seizures; Traumatic Brain Injuries; Traumatic Brain Injury (TBI) Patients
Sites: Chandigarh, India; Jodhpur, India; Lucknow, India
National Institute of Neurological Disorders and Stroke (NINDS)NIH
NCT02531880 · 40 participants (planned) · Start Nov 19, 2024 · Primary completion Jul 1, 2030
Drug: Mangafodipir; Gadolinium · For: Epilepsy
Sites: Bethesda, Maryland
- A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet SyndromePivotal-lookingRecruiting
Encoded TherapeuticsIndustry
NCT05419492 · 113 participants (planned) · Start May 14, 2024 · Primary completion Jun 2028
Drug: ETX101 · For: Dravet Syndrome
Sites: San Francisco, California; Aurora, Colorado; Miami, Florida · 14 sites in all
- Oxygen Toxicity: Mechanisms in HumansRecruiting
Duke UniversityAcademic, hospital or other
NCT05761756 · 62 participants (planned) · Start Nov 28, 2023 · Primary completion Dec 31, 2026
Drug: Caffeine; Methylphenidate and 1 more · For: Oxygen Toxicity; Hypercapnia; Seizures
Sites: Durham, North Carolina
- A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal SeizuresPivotal-lookingRecruiting
University of California, San DiegoAcademic, hospital or other
NCT05610085 · 133 participants (planned) · Start Mar 24, 2023 · Primary completion Jul 1, 2027
Drug: Levetiracetam Injection; Phenobarbital Sodium Injection · For: Neonatal Seizure; Neonatal Encephalopathy; Hypoxic-Ischemic Encephalopathy and 1 more
Sites: San Diego, California; Minneapolis, Minnesota; Auckland, New Zealand · 6 sites in all
- A Study to Evaluate the Safety, Efficacy, and PK of ONO-2017 in Japanese Patients With POS 2 to 17 Year OldsPivotal-lookingRecruiting
Ono Pharmaceutical Co., Ltd.Industry
NCT07594158 · 20 participants (planned) · Start Jun 10, 2026 · Primary completion Mar 30, 2028
Drug: Cenobamate (tablet) for 12 to < 18 year olds; Cenobamate (syrup) for 2 to < 18 year olds · For: Partial Epilepsy
Sites: Fukuoka, Japan
- An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut SyndromePivotal-lookingRecruiting
EpygenixIndustry
NCT05066217 · 260 participants (planned) · Start Apr 9, 2025 · Primary completion Nov 1, 2026
Drug: Clemizole HCl; Placebo · For: Lennox Gastaut Syndrome
Sites: Little Rock, Arkansas; Orange, California; Miami, Florida · 71 sites in all
University of Texas Southwestern Medical CenterAcademic, hospital or other
NCT05594017 · 60 participants (planned) · Start Aug 1, 2019 · Primary completion Nov 30, 2027
Drug: Scopolamine (0.4mg); Placebo · For: Epilepsy; Seizures; Cognitive Impairment, Mild and 2 more
Sites: Dallas, Texas
- Efficacy of Probenecid on Cluster Seizures During Anti Seizure Medication Withdrawal in Presurgical Focal Epilepsy Video-EEG MonitoringPivotal-lookingRecruiting
Fondation Ophtalmologique Adolphe de RothschildResearch network
NCT07318870 · 600 participants (planned) · Start Aug 24, 2026 · Primary completion Sep 2029
Drug: Probenecid · For: Focal Epilepsy
Sites: Paris, France · 2 sites in all
- RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset SeizuresPivotal-lookingRecruiting
Supernus Pharmaceuticals, Inc.Industry
NCT06798896 · 216 participants (planned) · Start Dec 30, 2024 · Primary completion Aug 2027
Drug: SPN-817; Placebo · For: Focal Onset Seizures
Sites: Phoenix, Arizona; Tucson, Arizona; Little Rock, Arkansas · 63 sites in all
Mayo ClinicAcademic, hospital or other
NCT07012148 · 12 participants (planned) · Start Jan 20, 2026 · Primary completion Dec 2028
Drug: Preventative Medication (PM) · For: Focal Epilepsy; Generalized Seizure; Drug Refractory Epilepsy
Sites: Scottsdale, Arizona; Jacksonville, Florida; Rochester, Minnesota
King Edward Medical UniversityAcademic, hospital or other
NCT07793396 · 1,500 participants (planned) · Start Dec 2, 2025 · Primary completion Dec 31, 2026
Drug: Eslicarbazepine acetate · For: Focal-Onset Seizures
Sites: Lahore, Pakistan
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.